Company intelligence / Profile preview

Sciele Pharma, Inc.

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

Prior to its acquisition by Shionogi in October 2008 for $1.1–$1.4 billion, Sciele was a commercial-stage specialty pharmaceutical company with a portfolio of branded prescription products focused on cardiovascular/metabolic diseases, women’s health, and pediatrics. The company had an established U.S. sales force and several marketed drugs but was not primarily a drug discovery or platform technology company.

Therapeutic areas: PulmonologyEndocrinologyPsychiatryCardiovascularWomen's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

adx415

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sciele Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sciele Pharma, Inc..

Explore the full profile